[go: up one dir, main page]

MX2020000595A - Regiones de unión al antígeno contra dominios de fibronectina tipo iii y métodos para su uso. - Google Patents

Regiones de unión al antígeno contra dominios de fibronectina tipo iii y métodos para su uso.

Info

Publication number
MX2020000595A
MX2020000595A MX2020000595A MX2020000595A MX2020000595A MX 2020000595 A MX2020000595 A MX 2020000595A MX 2020000595 A MX2020000595 A MX 2020000595A MX 2020000595 A MX2020000595 A MX 2020000595A MX 2020000595 A MX2020000595 A MX 2020000595A
Authority
MX
Mexico
Prior art keywords
methods
type iii
domain antibodies
fibronectin type
same
Prior art date
Application number
MX2020000595A
Other languages
English (en)
Inventor
Michael Naso
Chichi Huang
John Lee
Jill Mooney
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2020000595A publication Critical patent/MX2020000595A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Los anticuerpos de dominio de fibronectina tipo III (FN3), los polinucleótidos capaces de codificar los anticuerpos o fragmentos de unión al antígeno de dominio FN3, las células que expresan anticuerpos o fragmentos de unión al antígeno de dominio FN3, así como los vectores asociados y anticuerpos o fragmentos de unión al antígeno de dominio FN3 etiquetados de manera detectable pueden usarse para diseñar receptores de antígeno quimérico (CAR) dirigidos al dominio FN3; los métodos para fabricar los anticuerpos de dominio FN3, los CAR y las células inmunitarias diseñadas, y los métodos para usar las células inmunitarias diseñadas son aplicables para tratar enfermedades que incluyen el cáncer.
MX2020000595A 2017-07-17 2018-07-17 Regiones de unión al antígeno contra dominios de fibronectina tipo iii y métodos para su uso. MX2020000595A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762533341P 2017-07-17 2017-07-17
US201862625576P 2018-02-02 2018-02-02
PCT/US2018/042495 WO2019018402A2 (en) 2017-07-17 2018-07-17 ANTIGEN-BINDING REGIONS DIRECTED AGAINST FIBRONECTIN TYPE III DOMAINS AND METHODS OF USING THE SAME

Publications (1)

Publication Number Publication Date
MX2020000595A true MX2020000595A (es) 2020-09-10

Family

ID=65000212

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000595A MX2020000595A (es) 2017-07-17 2018-07-17 Regiones de unión al antígeno contra dominios de fibronectina tipo iii y métodos para su uso.

Country Status (11)

Country Link
US (2) US11161897B2 (es)
EP (1) EP3655026A4 (es)
JP (1) JP7280238B2 (es)
KR (1) KR102869563B1 (es)
CN (1) CN111093696B (es)
AU (2) AU2018304173A1 (es)
CA (1) CA3070100A1 (es)
IL (1) IL271982B2 (es)
MA (1) MA49652A (es)
MX (1) MX2020000595A (es)
WO (1) WO2019018402A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022001331A2 (pt) * 2019-07-26 2022-06-14 Janssen Biotech Inc Receptor quimérico de antígeno (car) anti-hk2
EP4045061A4 (en) * 2019-10-14 2024-04-17 ARO Biotherapeutics Company CD71-BINDING FIBRONECTIN TYPE III DOMAINS
US20220380447A1 (en) * 2019-11-01 2022-12-01 The Trustees Of The University Of Pennsylvania Fibronectin targeting chimeric antigen receptors (cars)
AU2021266735A1 (en) * 2020-05-05 2022-12-22 Aro Biotherapeutics Company Prostate specific membrane antigen binding fibronectin type III domains and cells comprising the same

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
DE69839147T2 (de) 1997-06-12 2009-02-19 Novartis International Pharmaceutical Ltd. Künstliche antikörperpolypeptide
ES2302726T3 (es) 2000-02-24 2008-08-01 Invitrogen Corporation Estimulacion y concentracion simultanea de celulas.
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US20130226834A1 (en) 2000-04-27 2013-08-29 Networth Services, Inc. Systems and methods for determining the financial status of bonds
FR2844519A1 (fr) * 2002-09-17 2004-03-19 Bio Merieux Proteine recombinante chimerique et diagnostic in vitro
US8703134B2 (en) * 2003-05-15 2014-04-22 Iogenetics, Llc Targeted cryptosporidium biocides
EP1711527A4 (en) 2003-12-15 2008-09-03 Dendreon Corp HLA-DR SPECIFIC ANTIBODIES, COMPOSITIONS AND METHODS
AU2005337132B2 (en) * 2004-12-21 2011-01-20 Monsanto Technology, Llc Transgenic plants with enhanced agronomic traits
WO2007059782A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
WO2010051274A2 (en) 2008-10-31 2010-05-06 Centocor Ortho Biotech Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
IT1392027B1 (it) * 2008-12-12 2012-02-09 Castellani Anticorpo monoclonale e suo uso per la identificazione della isoforma oncofetale della fibronettina (b-fn) a scopo diagnostico o terapeutico.
US20100317539A1 (en) 2009-06-12 2010-12-16 Guo-Liang Yu Library of Engineered-Antibody Producing Cells
ES2624835T3 (es) * 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
ES2566602T3 (es) * 2010-04-09 2016-04-14 Aveo Pharmaceuticals, Inc. Anticuerpos anti-ErbB3
PT3103478T (pt) 2010-04-30 2019-07-10 Janssen Biotech Inc Composições, métodos e utilizações de domínios de fibronectinas estabilizadas
JP5857060B2 (ja) 2010-11-03 2016-02-10 アルゲン−エックス エヌ．ブイ． 抗ｃ−Ｍｅｔ抗体
SG190952A1 (en) * 2010-12-02 2013-07-31 Univ Washington Compositions and methods for treating amyloid plaque associated symptoms
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN106074601A (zh) 2011-03-23 2016-11-09 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
WO2013176915A1 (en) 2012-05-25 2013-11-28 Roman Galetto Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
US20150017136A1 (en) 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
BR112015004522A2 (pt) 2012-09-04 2017-11-21 Cellectis receptor de antígeno quimérico multicadeia e usos destes
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
JP6758832B2 (ja) * 2012-12-21 2020-09-30 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｇｄｆ１５抗体
EP2958942B1 (en) 2013-02-20 2020-06-03 Novartis AG Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
US9790282B2 (en) * 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
EP2997133B1 (en) 2013-05-13 2023-08-23 Cellectis Methods for engineering highly active t cell for immunotherapy
RS63798B1 (sr) 2013-05-13 2022-12-30 Cellectis Cd19 specifični himerni antigenski receptor i njegove primene
EP3004337B1 (en) 2013-05-29 2017-08-02 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
RU2694659C2 (ru) * 2014-01-06 2019-07-16 Ф. Хоффманн-Ля Рош Аг Одновалентные модули-переносчики через гематоэнцефалический барьер
SG10202109752XA (en) * 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
IL254039B2 (en) * 2015-02-19 2023-12-01 Compugen Ltd Anti-pvrig antibodies and methods of use
IL254817B2 (en) * 2015-04-08 2023-12-01 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
HK1253005A1 (zh) * 2015-05-06 2019-06-06 Janssen Biotech, Inc. 前列腺特异性膜抗原结合iii型纤连蛋白结构域
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
US10688178B2 (en) * 2015-06-30 2020-06-23 Osaka University AntiPlexin A1 agonist antibody
US11078286B2 (en) * 2015-09-20 2021-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use
TWI744261B (zh) * 2015-11-24 2021-11-01 荷蘭商拜恩迪斯公司 抗５ｔ４抗體和抗體-藥物共軛體
WO2017118307A1 (zh) * 2016-01-05 2017-07-13 江苏恒瑞医药股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
EP3512541A1 (en) * 2016-09-14 2019-07-24 Janssen Biotech, Inc. Chimeric antigen receptors comprising bcma-specific fibronectin type iii domains and uses thereof
WO2019118475A1 (en) * 2017-12-13 2019-06-20 Janssen Biotech, Inc. Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression

Also Published As

Publication number Publication date
CN111093696A (zh) 2020-05-01
KR102869563B1 (ko) 2025-10-10
CN111093696B (zh) 2023-10-27
EP3655026A4 (en) 2021-07-28
IL271982A (en) 2020-02-27
KR20200028447A (ko) 2020-03-16
WO2019018402A2 (en) 2019-01-24
US11161897B2 (en) 2021-11-02
AU2025204213A1 (en) 2025-06-26
CA3070100A1 (en) 2019-01-24
IL271982B1 (en) 2024-10-01
EP3655026A2 (en) 2020-05-27
JP2020530766A (ja) 2020-10-29
AU2018304173A1 (en) 2020-01-30
JP7280238B2 (ja) 2023-05-23
WO2019018402A3 (en) 2019-02-28
US12269870B2 (en) 2025-04-08
US20190016789A1 (en) 2019-01-17
IL271982B2 (en) 2025-02-01
US20220127343A1 (en) 2022-04-28
MA49652A (fr) 2020-05-27

Similar Documents

Publication Publication Date Title
ZA202311412B (en) Anti-phf-tau antibodies and uses thereof
MX2017001013A (es) Tratamiento de cáncer usando un receptor quimérico de antígeno cll-1.
PH12019500750A1 (en) Chimeric antigen receptors for the treatment of cancer
MX2015013194A (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 humanizado.
MX2020003046A (es) Anticuerpos anti-hla-a2 y metodos para utilizar los mismos.
EP3593812A3 (en) Treatment of cancer using chimeric antigen receptor
MY181834A (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor
PH12020551997A1 (en) Psma binding agents and uses thereof
PH12020551160A1 (en) Chimeric antigen receptors targeting cd70
MX2022015823A (es) Receptores de antigenos quimerlcos basados en anticuerpos de dominio simple y metodos de uso de estos.
MX2019001184A (es) Anticuerpos anti-idiotípicos y métodos relacionados.
PH12018502113A1 (en) Chimeric receptors and methods of use thereof
MX374929B (es) RECEPTOR QUIMERICO DE ANTIGENO anti-EGFRvlll HUMANIZADO Y USOS DEL MISMO.
MX2019000643A (es) Receptores de antigenos quimericos y metodos de uso.
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
NZ759835A (en) Cd38 modulating antibody
PH12018501902A1 (en) Gitr antibodies, methods, and uses
MX2020000595A (es) Regiones de unión al antígeno contra dominios de fibronectina tipo iii y métodos para su uso.
MX2021000287A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
JOP20200106A1 (ar) جسم مضاد أحادي النسيلة مضاد لـ il-5r?
MX2021000280A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
MX2021000288A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
MX2021000305A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
EA202090278A1 (ru) Антигенсвязывающие области против доменов фибронектина типа iii и способы их применения
HK1231900A1 (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor